Liege - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces the invitation to its extraordinary securities holders' meeting that will be held on Friday October 21 2022 at 2:00 PM (CEST) at Mithra CDMO, rue de l'Expansion 57 in 4400 Flemalle (Belgium).

The notice for the extraordinary general meeting including a description of the formalities to participate in the meeting is available on the website investors.mithra.com.

Exceptional organisational arrangements due to Covid-19

Considering the COVID-19 pandemic, it is possible that our governments and public authorities may adapt the conditions and modalities for physical participation in the extraordinary general meeting. We reserve our rights to issue additional instructions in this regard. These measures are in the interest of the health of the individual security holders, as well as of the Company's employees and other persons responsible for organizing the extraordinary general meeting. Therefore, the Company recommends that shareholders of the Company who wish to participate in the extraordinary general meeting use, to the extent possible, the right to vote by mail or by proxy containing specific voting instructions for each proposed decision granted to Fanny Rozenberg, secretary of the Board of Directors of the Company, and not to attend the extraordinary general meeting personally. The Company will grant access to the general meeting to security holders, proxy holders and any other persons only to the extent permitted by the measures taken or to be taken by the authorities, as applicable at the time of the extraordinary general meeting, and always taking into account the recommendations of the authorities, as well as safety and health considerations.

In addition, holders of the Company's securities are encouraged to exercise their right to ask questions in writing concerning the items on the agenda of the extraordinary general meeting. Details of how to participate in the extraordinary shareholders' meeting are set out in this notice of meeting.

All procedures for attending the extraordinary shareholders' meetings are indicated in the present meeting's invitation.

Contact:

Benoit Mathieu

Tel: +32 473 35 80 18

Email: investorrelations@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle, Mithra is now focusing on its second product Donesta, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormonedependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liege, Belgium.

(C) 2022 Electronic News Publishing, source ENP Newswire